Results 31 to 40 of about 214,432 (171)

Clinical outcomes and molecular characterization of drug-resistant tuberculosis in pre- and extensively drug-resistant disease based on line probe assays

Brazilian Journal of Infectious Diseases, 2021
Multidrug-resistant tuberculosis (MDR-TB) represents a significant impact in transmission, outcome, and health costs. The World Health Organization recommends implementation of rapid diagnostic methods for multidrug-resistance detection.
Lauane G. Araújo, Márcia T. Garcia, Tânia R. Zaccariotto, Maria Luiza Moretti, Carlos E. Levy, Mariângela R. Resende   +5 more
doaj   +1 more source

The Emergence of Extensively Drug-Resistant Tuberculosis (TB): TB/HIV Coinfection, Multidrug-Resistant TB and the Resulting Public Health Threat from Extensively Drug-Resistant TB, Globally and in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology, 2007
Resistance to anti-tuberculosis (TB) drugs continues to present a major challenge to global public health. Resistance usually develops due to inadequate TB management, including improper use of medications, improper treatment regimens and failure to ...
Paul E Alexander, Prithwish De
doaj   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

XDR TB in South Africa - What lies ahead? [PDF]

, 2007
The emergence of XDR TB coupled with the high prevalence of HIV/AIDS has intensified the need to identify new treatment strategies and accelerate research into antibiotics against XDR TB before the world is faced with a global public health crisis.
Ogunbanjo, Gboyega A., Thaver, V.
core   +2 more sources

XDR TB [PDF]

Extensively drug resistant TB (XDR TB) is a rare type of multidrug-resistant tuberculosis (MDR TB) that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.) Division of Tuberculosis Elimination.
core   +4 more sources

Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. [PDF]

PLoS ONE, 2013
BACKGROUND: India with a major burden of multidrug-resistant tuberculosis (MDR-TB) does not have national level data on this hazardous disease. Since 2006, emergence of extensively drug-resistant TB (XDR-TB) is considered a serious threat to global TB ...
Chhavi Porwal, Amit Kaushik, Nayani Makkar, Jayant N Banavaliker, Mahmud Hanif, Rupak Singla, Anuj K Bhatnagar, Digambar Behera, Jitendra Nath Pande, Urvashi B Singh   +9 more
doaj   +1 more source

High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates

Emerging Microbes and Infections, 2022
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) make TB difficult to control. Global susceptibility data for six newly recommended anti-TB drugs against M/XDR-TB are still limited.
Kanwara Trisakul, Ditthawat Nonghanphithak, Pratchakan Chaiyachat, Orawee Kaewprasert, Kankanon Sakmongkoljit, Wipa Reechaipichitkul, Angkana Chaiprasert, David Blair, Taane G. Clark, Kiatichai Faksri   +9 more
doaj   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Patterns of Drug Resistance, Drug Resistance Conferring Mutations and Genomic DNA Methylation Revealed in Mycobacterium tuberculosis From South Africa

Tropical Medicine &International Health, EarlyView.
ABSTRACT Tuberculosis remains a major public health threat globally, with drug‐resistant strains undermining treatment efficacy. We analyzed 126 Mycobacterium tuberculosis (M. tuberculosis) isolates with diverse drug resistance spectra and selected 35 for whole genome sequencing (WGS) using Illumina NextSeq, SMRT PacBio Onso and SMRT PacBio Revio ...
Unarine Matodzi, Awelani Mutshembele, Eric Mensah, Dillon Muzondiwa, Ndivhuho A. Makhado, Oleg N. Reva   +5 more
wiley   +1 more source

Post‐Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management

MedComm, Volume 7, Issue 10, October 2026.
A comprehensive review on post‐tuberculosis lung disease (PTLD) addresses the epidemiology, pathogenesis, clinical phenotypes and management, risk factors, prevention and systems approach, and future directions. This review provides standardized definitions, mechanistic insights and biomarkers of PTLD development, and clinical strategies for PTLD ...
Radha Gopalaswamy, Selvakumar Subbian
wiley   +1 more source